Q-omics provides the consensus-scored KANK1 profile across patient tissues and cancer cell-line models. KANK1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KANK1 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, KANK1 protein abundance shows 34,929 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, BLCA, and PDAC as cancer lineages where KANK1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KANK1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KANK1 survival associations across molecular data types. KANK1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KANK1 RNA expression–survival associations across cancer types. High KANK1 expression shows unfavorable associations in SCLC and CESC, but favorable associations in KIRC, LUAD, LGG and GBM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KANK1 RNA expression.
This table summarizes KANK1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 12. The strongest signals are observed in LUAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for KANK1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KANK1 shows lower tumor expression in BLCA, LUAD, HNSC, BRCA and THCA and higher tumor expression in COAD. The BLCA box plot shows higher KANK1 RNA expression in normal versus tumor tissue (log2 FC = −2.292, t-test p < 0.001).
This table shows molecular features associated with KANK1 in patient tissues and cancer cell lines. In patient samples, KANK1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, KANK1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
